These findings support efforts to confirm the predictive value of CREBBP mutations in a larger cohort of newly-diagnosed GCB DLBCL/HGBL patients as well investigation of agents such as histone deacetylase inhibitors which may overcome loss of histone acetyltransferase function in patients with CREBBP-mutated GCB DLBCL/HGBL. Here, CREBBP is linked to diffuse large B-cell lymphoma.